D2-40 in breast cancer: Should we detect more vascular emboli?

Modern Pathology

Volumn 22, Issue 2, 2009, Pages 216-222

  De Mascarel, Isabelle ^a   MacGrogan, Gaëtan ^a   Debled, Marc ^a   Sierankowski, Ghislaine ^a   Brouste, Véronique ^a   Mathoulin Pélissier, Simone ^a   Mauriac, Louis ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Breast cancer; D2 40; Immunohistochemistry; Lymphovascular invasion; Prognosis

Indexed keywords

EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY D2-40;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CELL COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EXTENSION GENE; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LONG TERM CARE; LYMPH NODE; LYMPH VESSEL; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TOPOGRAPHY; TUMOR EMBOLISM; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BLOOD VESSELS; BREAST NEOPLASMS; CARCINOMA; COLORING AGENTS; EMBOLISM; EOSINE YELLOWISH-(YS); FALSE NEGATIVE REACTIONS; FEMALE; HEMATOXYLIN; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; TIME FACTORS; TREATMENT OUTCOME;

EID: 59149097979     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.151     Document Type: Article

References (33)

1. Nime F, Rosen PP, Thaler H, et al. Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma. Am J Surg Pathol 1977;1:25-30.
2. Rosen PP, Saigo PE, Braun DW, et al. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg 1981;193:15-25.
3. Rosen PP. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu 1983;18(Part 2):215-232.
4. de Mascarel I, Bonichon F, Durand M, et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 1998;34:58-65.
5. Lee AH, Pinder SE, Macmillan RD, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006;42:357-362.
6. Trudeau ME, Pritchard KI, Chapman JA, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 2005;89:35-45.
7. Goldhirsch A, Coates AS, Gelber RD, et al. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006;17:1772-1776.
8. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
9. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumors. Br J Cancer 1999;80:569-578.
10. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-440.
11. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathol 2005;46:396-402.
12. Arnaout-Alkarain A, Kahn HJ, Narod SA, et al. Significance of lymph vessel invasion identified by the lymphatic marker D2-40 in node negative breast cancer. Mod Pathol 2007;20:183-191.
13. Niakosari F, Kahn HJ, Marks AN, et al. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol 2005;141:440-444.
14. Bui Nguyen Binh-Desrousseaux M. Mise en place d'un tissu micro-array pronostique dans le cancer du sein. A propos de 855 cas de carcinomes canalaires infiltrants. Université de Bordeaux 2 2005, Thèse N13058 (submitted).
15. Mauriac L, Durand M, Chauvergne J, et al. Adjuvant trial for stage II receptor positive breast cancer: CMF vs CMF+tamoxifen in single centre. Breast Cancer Res Treat 1988;11:179-186.
16. Mauriac L, Durand M, Chauvergne J, et al. Cancers of the breast at metastatic high-risk: prediction of survival by steroidal receptors. Les cancers du sein à haut risque métastatique: prédiction de la survie par les récepteurs stéroidiens. Bull Cancer Paris 1989;76:33-41.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
18. Rosen PP, Oberman HA. Tumors of the mammary gland. Washington: Armed Forces Institute of Pathology, 1993, 390 p.
19. Rosen PP. Rosen's Breast Pathology, 2nd edn. Lippincot Williams & Wilkins editor: Philadelphia, 2001.
20. Colleoni M, Rotmensz N, Maisonneuve P, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 2007;18:1632-1640.
21. Mohammed RA, Martin SG, Gill MS, et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007;31:1825-1833.
22. Braun M, Flicke U, Debald M, et al. Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases. Breast Cancer Res Treat 2007; e-pub ahead of print.
23. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer. A prospective immunohistochemical study. Br J Cancer 2006;94:1643-1649.
24. Karpanen T, Egeblard M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumout lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-1790.
25. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth facto-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672-682.
26. Stacker SA, Stacker SA, Caesar C, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatic. Nat Med 2001;7:186-191.
27. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-198.
28. Schoppmann SF, Fenzl A, Nagy K, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006;139:839-846.
29. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005;91:125-132.
30. Massi D, Puig S, Franchi A, et al. Tumor lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 2006;59:166-173.
31. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005;18:1232-1242.
32. Jia YT, Li ZX, He YT, et al. Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer. World J Gastroenterol 2004;10:3261-3263.
33. Huang JH, Li Y, Liu L, et al. Lymphangiogenesis and location of tumor lymphatic vessels induced by VEGF-C in primary breast cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006;31:36-39, 51.